Are you over 18 and want to see adult content?
More Annotations
A complete backup of c2-shade.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of szabadmagyarszo.com
Are you over 18 and want to see adult content?
A complete backup of prismbrainmapping.com
Are you over 18 and want to see adult content?
A complete backup of playstationtrophies.org
Are you over 18 and want to see adult content?
A complete backup of ericssoncooperative.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://ltbridge.com
Are you over 18 and want to see adult content?
A complete backup of https://cebusal.es
Are you over 18 and want to see adult content?
A complete backup of https://eapon.ca
Are you over 18 and want to see adult content?
A complete backup of https://medoo.in
Are you over 18 and want to see adult content?
A complete backup of https://samedi.de
Are you over 18 and want to see adult content?
A complete backup of https://incognito.org
Are you over 18 and want to see adult content?
A complete backup of https://acf-inc.com
Are you over 18 and want to see adult content?
A complete backup of https://alldayidreamaboutfood.com
Are you over 18 and want to see adult content?
A complete backup of https://braillebattery.com
Are you over 18 and want to see adult content?
Text
PRESS RELEASES
Press Releases. Date. Title. Files. May 27, 2021. Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany. PDF Version. May 19, 2021. Dynavax to Present at the William Blair 41st Annual Growth Stock Conference. JOB OPPORTUNITIES AT DYNAVAX TECHNOLOGIES Dynavax is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status. HEPLISAV-B | DYNAVAX TECHNOLOGIES HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. 1 HEPLISAV-B recommended by CDC Advisory Committee on Immunization Practices (ACIP) for the Prevention of Hepatitis B in Adults. 2 INDICATION POSITIVE PHASE 1/2 RESULTS FOR VALNEVA'S INACTIVATED COVID EMERYVILLE, Calif., April 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Valneva SE reported positive initial results for Part A of the Phase 1/2 clinical trial of Valneva's inactivated COVID-19 vaccine candidate, VLA2001, using Dynavax's CpG CPG 1018 | TOLL-LIKE RECEPTOR 9 (TLR9) AGONIST ADJUVANT CpG 1018. CpG 1018 has been studied clinically and developed as a vaccine adjuvant for Dynavax’s hepatitis B vaccine, HEPLISAV-B. The pre-clinical and clinical studies demonstrate that the addition of CpG 1018 increases antibody concentrations, stimulates helper (CD4+) and cytotoxic (CD8+) T cell populations and generates robust T and B cell DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate; EMERYVILLE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, andDYNAVAX EUROPE
OPTIMIZATION, PRODUCTION, AND CHARACTERIZATION OF A CPG polypropylene sulfide nanospheres,17 cationic PLG and emulsion/CpG nanoparticles, CAPO4 nanoparticles,18 CpG- loaded VLP,19 and CpG-liposomes.20 Herein, we describe the synthesis and formulation ofa CpG-
DYNAVAX TECHNOLOGIES COVID-19 Information and Resources. During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B ® ; maintaining our financial strength and ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.PRESS RELEASES
Press Releases. Date. Title. Files. May 27, 2021. Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany. PDF Version. May 19, 2021. Dynavax to Present at the William Blair 41st Annual Growth Stock Conference. JOB OPPORTUNITIES AT DYNAVAX TECHNOLOGIES Dynavax is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status. HEPLISAV-B | DYNAVAX TECHNOLOGIES HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. 1 HEPLISAV-B recommended by CDC Advisory Committee on Immunization Practices (ACIP) for the Prevention of Hepatitis B in Adults. 2 INDICATION POSITIVE PHASE 1/2 RESULTS FOR VALNEVA'S INACTIVATED COVID EMERYVILLE, Calif., April 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Valneva SE reported positive initial results for Part A of the Phase 1/2 clinical trial of Valneva's inactivated COVID-19 vaccine candidate, VLA2001, using Dynavax's CpG CPG 1018 | TOLL-LIKE RECEPTOR 9 (TLR9) AGONIST ADJUVANT CpG 1018. CpG 1018 has been studied clinically and developed as a vaccine adjuvant for Dynavax’s hepatitis B vaccine, HEPLISAV-B. The pre-clinical and clinical studies demonstrate that the addition of CpG 1018 increases antibody concentrations, stimulates helper (CD4+) and cytotoxic (CD8+) T cell populations and generates robust T and B cell DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate; EMERYVILLE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, andDYNAVAX EUROPE
OPTIMIZATION, PRODUCTION, AND CHARACTERIZATION OF A CPG polypropylene sulfide nanospheres,17 cationic PLG and emulsion/CpG nanoparticles, CAPO4 nanoparticles,18 CpG- loaded VLP,19 and CpG-liposomes.20 Herein, we describe the synthesis and formulation ofa CpG-
ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation. CONTACT DYNAVAX TECHNOLOGIES Dynavax Technologies Corporation. 2100 Powell Street, Suite 900 Emeryville, CA 94608 Phone: +1.510.848.5100 Toll Free: +1.877.848.5100 Fax: +1.510.848.1327 CAREERS AT DYNAVAX TECHNOLOGIES Join Our Team. Dynavax is focused on developing innovative therapies based on breakthroughs in scientific discovery to make a difference in the lives of patients. We are a dynamic team with diverse backgrounds, and we like it that way. We are a values-based organization that looks out for our employees and fosters a rewarding work environment.INVESTOR RELATIONS
Dynavax Overview. Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation to develop cutting-edge vaccines. The Company’s first commercial product, HEPLISAV-B® ,a
ONGOING STUDIES LISTING Ongoing Studies DV2-HBV-25 (Post-marketing Study for Acute Myocardial Infarction Events) The HBV-25 post-marketing observational surveillance study began in August 2018 and will evaluate the occurrence of acute myocardial infarction (AMI) in approximately 30,000 patients who receive HEPLISAV-B ® and approximately 30,000 patients who receive another hepatitis B vaccine. MEDIGEN'S COVID-19 VACCINE COMBINED WITH DYNAVAX'S CPG MVC's Phase 1 study is an open-label, single-center, staggered dose-escalation study intended to assess the safety and immunogenicity of the stable prefusion form of SARS-CoV-2 recombinant spike protein S-2P at three dose levels (low, medium and high) adjuvanted with CpG 1018 plus alum, in approximately 45 healthy subjects 20 to 50 years ofage.
DYNAVAX ANNOUNCES EXERCISE OF OPTION TO RESERVE ADDITIONAL In September 2020, the companies announced a commercial partnership for the supply of Dynavax's CpG 1018 adjuvant for use in VLA2001, to support Valneva's agreement with the U.K. government to provide up to 190 million doses of VLA2001 over a five-year period. Dynavax expects to supply CpG 1018 to produce up to 100 million doses of vaccine in 2021. . Valneva has the option to DYNAVAX ANNOUNCES GRANT TO SCALE UP CPG 1018 ADJUVANT EMERYVILLE, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a grant from the Bill & Melinda Gates Foundation of $3.4 million to scale up production batch size to allow for increased capacity of Dynavax’s CpG 1018 advanced adjuvant to DYNAVAX ANNOUNCES STRATEGIC RESTRUCTURING TO FOCUS ON ITS The Investor Relations website contains information about Dynavax Technologies Corporation's business for stockholders, potential investors, and financial analysts. DYNAVAX'S HEPLISAV-B™ [HEPATITIS B VACCINE (RECOMBINANT BERKELEY, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously in favor of including HEPLISAV-B on its list of ACIP recommended products for use to vaccinate adults against hepatitis B. HEPLISAV-B was DYNAVAX TECHNOLOGIES COVID-19 Information and Resources. During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B ® ; maintaining our financial strength and ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation. JOB OPPORTUNITIES AT DYNAVAX TECHNOLOGIES Dynavax is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status.INVESTOR RELATIONS
Dynavax Overview. Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation to develop cutting-edge vaccines. The Company’s first commercial product, HEPLISAV-B® ,a
PRESS RELEASES
Press Releases. Date. Title. Files. May 27, 2021. Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany. PDF Version. May 19, 2021. Dynavax to Present at the William Blair 41st Annual Growth Stock Conference. DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate; EMERYVILLE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, andDYNAVAX EUROPE
DYNAVAX ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF Dynavax is providing CpG 1018, the adjuvant contained in HEPLISAV-B, to support the rapid development of a COVID-19 vaccine. EMERYVILLE, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it is collaborating with the University of QueenslandBRENT MACGREGOR
Brent MacGregor. Mr. MacGregor was appointed to the Dynavax board in July 2020. Mr. MacGregor previously served as Senior Vice-President, Global Commercial Operations at Seqirus, a CSL Limited company. At Seqirus, Mr. MacGregor led a global team of 280 people in sales, marketing, commercial development, public policy and businessdevelopment
DYNAVAX'S HEPLISAV-B™ [HEPATITIS B VACCINE (RECOMBINANT BERKELEY, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously in favor of including HEPLISAV-B on its list of ACIP recommended products for use to vaccinate adults against hepatitis B. HEPLISAV-B was DYNAVAX TECHNOLOGIES COVID-19 Information and Resources. During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B ® ; maintaining our financial strength and ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation. JOB OPPORTUNITIES AT DYNAVAX TECHNOLOGIES Dynavax is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status.INVESTOR RELATIONS
Dynavax Overview. Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation to develop cutting-edge vaccines. The Company’s first commercial product, HEPLISAV-B® ,a
PRESS RELEASES
Press Releases. Date. Title. Files. May 27, 2021. Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany. PDF Version. May 19, 2021. Dynavax to Present at the William Blair 41st Annual Growth Stock Conference. DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate; EMERYVILLE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, andDYNAVAX EUROPE
DYNAVAX ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF Dynavax is providing CpG 1018, the adjuvant contained in HEPLISAV-B, to support the rapid development of a COVID-19 vaccine. EMERYVILLE, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it is collaborating with the University of QueenslandBRENT MACGREGOR
Brent MacGregor. Mr. MacGregor was appointed to the Dynavax board in July 2020. Mr. MacGregor previously served as Senior Vice-President, Global Commercial Operations at Seqirus, a CSL Limited company. At Seqirus, Mr. MacGregor led a global team of 280 people in sales, marketing, commercial development, public policy and businessdevelopment
DYNAVAX'S HEPLISAV-B™ [HEPATITIS B VACCINE (RECOMBINANT BERKELEY, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously in favor of including HEPLISAV-B on its list of ACIP recommended products for use to vaccinate adults against hepatitis B. HEPLISAV-B was ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation. CONTACT DYNAVAX TECHNOLOGIES Dynavax Technologies Corporation. 2100 Powell Street, Suite 900 Emeryville, CA 94608 Phone: +1.510.848.5100 Toll Free: +1.877.848.5100 Fax: +1.510.848.1327 CAREERS AT DYNAVAX TECHNOLOGIES Join Our Team. Dynavax is focused on developing innovative therapies based on breakthroughs in scientific discovery to make a difference in the lives of patients. We are a dynamic team with diverse backgrounds, and we like it that way. We are a values-based organization that looks out for our employees and fosters a rewarding work environment. S-TRIMER, A COVID-19 SUBUNIT VACCINE CANDIDATE, INDUCES 4 gp120, but not monomeric gp120 (14-17), implies that preserving the native trimeric conformation of viral antigens may be important to thefuture success of
ONGOING STUDIES
Dynavax Technologies ongoing studies, we have a number of ongoing clinical post marketing and investigational studies. POSITIVE PHASE 1/2 RESULTS FOR VALNEVA'S INACTIVATED COVID EMERYVILLE, Calif., April 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Valneva SE reported positive initial results for Part A of the Phase 1/2 clinical trial of Valneva's inactivated COVID-19 vaccine candidate, VLA2001, using Dynavax's CpG HEPLISAV-B | DYNAVAX TECHNOLOGIES HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. 1 HEPLISAV-B recommended by CDC Advisory Committee on Immunization Practices (ACIP) for the Prevention of Hepatitis B in Adults. 2 INDICATION MEDIGEN'S COVID-19 VACCINE COMBINED WITH DYNAVAX'S CPG MVC's Phase 1 study is an open-label, single-center, staggered dose-escalation study intended to assess the safety and immunogenicity of the stable prefusion form of SARS-CoV-2 recombinant spike protein S-2P at three dose levels (low, medium and high) adjuvanted with CpG 1018 plus alum, in approximately 45 healthy subjects 20 to 50 years ofage.
DYNAVAX ANNOUNCES AGREEMENT WITH BAVARIAN NORDIC FOR EMERYVILLE, Calif., May 27, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B in DYNAVAX ANNOUNCES STRATEGIC RESTRUCTURING TO FOCUS ON ITS The Investor Relations website contains information about Dynavax Technologies Corporation's business for stockholders, potential investors, and financial analysts. DYNAVAX TECHNOLOGIES COVID-19 Information and Resources. During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B ® ; maintaining our financial strength and ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.INVESTOR RELATIONS
Dynavax Overview. Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation to develop cutting-edge vaccines. The Company’s first commercial product, HEPLISAV-B® ,a
JOB OPPORTUNITIES AT DYNAVAX TECHNOLOGIES Dynavax is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status.PRESS RELEASES
Press Releases. Date. Title. Files. May 27, 2021. Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany. PDF Version. May 19, 2021. Dynavax to Present at the William Blair 41st Annual Growth Stock Conference. CPG 1018 | TOLL-LIKE RECEPTOR 9 (TLR9) AGONIST ADJUVANT CpG 1018. CpG 1018 has been studied clinically and developed as a vaccine adjuvant for Dynavax’s hepatitis B vaccine, HEPLISAV-B. The pre-clinical and clinical studies demonstrate that the addition of CpG 1018 increases antibody concentrations, stimulates helper (CD4+) and cytotoxic (CD8+) T cell populations and generates robust T and B cell DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate; EMERYVILLE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, andDYNAVAX EUROPE
BRENT MACGREGOR
Brent MacGregor. Mr. MacGregor was appointed to the Dynavax board in July 2020. Mr. MacGregor previously served as Senior Vice-President, Global Commercial Operations at Seqirus, a CSL Limited company. At Seqirus, Mr. MacGregor led a global team of 280 people in sales, marketing, commercial development, public policy and businessdevelopment
DYNAVAX'S HEPLISAV-B™ [HEPATITIS B VACCINE (RECOMBINANT BERKELEY, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously in favor of including HEPLISAV-B on its list of ACIP recommended products for use to vaccinate adults against hepatitis B. HEPLISAV-B was DYNAVAX TECHNOLOGIES COVID-19 Information and Resources. During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B ® ; maintaining our financial strength and ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation. JOB OPPORTUNITIES AT DYNAVAX TECHNOLOGIES Dynavax is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status.INVESTOR RELATIONS
Dynavax Overview. Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation to develop cutting-edge vaccines. The Company’s first commercial product, HEPLISAV-B® ,a
PRESS RELEASES
Press Releases. Date. Title. Files. May 27, 2021. Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany. PDF Version. May 19, 2021. Dynavax to Present at the William Blair 41st Annual Growth Stock Conference. CPG 1018 | TOLL-LIKE RECEPTOR 9 (TLR9) AGONIST ADJUVANT CpG 1018. CpG 1018 has been studied clinically and developed as a vaccine adjuvant for Dynavax’s hepatitis B vaccine, HEPLISAV-B. The pre-clinical and clinical studies demonstrate that the addition of CpG 1018 increases antibody concentrations, stimulates helper (CD4+) and cytotoxic (CD8+) T cell populations and generates robust T and B cell DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate; EMERYVILLE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, andDYNAVAX EUROPE
BRENT MACGREGOR
Brent MacGregor. Mr. MacGregor was appointed to the Dynavax board in July 2020. Mr. MacGregor previously served as Senior Vice-President, Global Commercial Operations at Seqirus, a CSL Limited company. At Seqirus, Mr. MacGregor led a global team of 280 people in sales, marketing, commercial development, public policy and businessdevelopment
DYNAVAX'S HEPLISAV-B™ [HEPATITIS B VACCINE (RECOMBINANT BERKELEY, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously in favor of including HEPLISAV-B on its list of ACIP recommended products for use to vaccinate adults against hepatitis B. HEPLISAV-B was HEPLISAV-B | DYNAVAX TECHNOLOGIES HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. 1 HEPLISAV-B recommended by CDC Advisory Committee on Immunization Practices (ACIP) for the Prevention of Hepatitis B in Adults. 2 INDICATION CAREERS AT DYNAVAX TECHNOLOGIES Join Our Team. Dynavax is focused on developing innovative therapies based on breakthroughs in scientific discovery to make a difference in the lives of patients. We are a dynamic team with diverse backgrounds, and we like it that way. We are a values-based organization that looks out for our employees and fosters a rewarding work environment. CONTACT DYNAVAX TECHNOLOGIES Dynavax Technologies Corporation. 2100 Powell Street, Suite 900 Emeryville, CA 94608 Phone: +1.510.848.5100 Toll Free: +1.877.848.5100 Fax: +1.510.848.1327 S-TRIMER, A COVID-19 SUBUNIT VACCINE CANDIDATE, INDUCES 4 gp120, but not monomeric gp120 (14-17), implies that preserving the native trimeric conformation of viral antigens may be important to thefuture success of
ONGOING STUDIES LISTING Ongoing Studies DV2-HBV-25 (Post-marketing Study for Acute Myocardial Infarction Events) The HBV-25 post-marketing observational surveillance study began in August 2018 and will evaluate the occurrence of acute myocardial infarction (AMI) in approximately 30,000 patients who receive HEPLISAV-B ® and approximately 30,000 patients who receive another hepatitis B vaccine. MEDIGEN'S COVID-19 VACCINE COMBINED WITH DYNAVAX'S CPG MVC's Phase 1 study is an open-label, single-center, staggered dose-escalation study intended to assess the safety and immunogenicity of the stable prefusion form of SARS-CoV-2 recombinant spike protein S-2P at three dose levels (low, medium and high) adjuvanted with CpG 1018 plus alum, in approximately 45 healthy subjects 20 to 50 years ofage.
ONGOING STUDIES
Dynavax Technologies ongoing studies, we have a number of ongoing clinical post marketing and investigational studies. DYNAVAX ANNOUNCES AGREEMENT WITH BAVARIAN NORDIC FOR EMERYVILLE, Calif., May 27, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B in DYNAVAX ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF Dynavax is providing CpG 1018, the adjuvant contained in HEPLISAV-B, to support the rapid development of a COVID-19 vaccine. EMERYVILLE, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it is collaborating with the University of Queensland DYNAVAX ANNOUNCES STRATEGIC RESTRUCTURING TO FOCUS ON ITS The Investor Relations website contains information about Dynavax Technologies Corporation's business for stockholders, potential investors, and financial analysts. DYNAVAX TECHNOLOGIES COVID-19 Information and Resources. During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B ® ; maintaining our financial strength and ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.INVESTOR RELATIONS
Dynavax Overview. Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation to develop cutting-edge vaccines. The Company’s first commercial product, HEPLISAV-B® ,a
JOB OPPORTUNITIES AT DYNAVAX TECHNOLOGIES Dynavax is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status.PRESS RELEASES
Press Releases. Date. Title. Files. May 27, 2021. Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany. PDF Version. May 19, 2021. Dynavax to Present at the William Blair 41st Annual Growth Stock Conference. CPG 1018 | TOLL-LIKE RECEPTOR 9 (TLR9) AGONIST ADJUVANT CpG 1018. CpG 1018 has been studied clinically and developed as a vaccine adjuvant for Dynavax’s hepatitis B vaccine, HEPLISAV-B. The pre-clinical and clinical studies demonstrate that the addition of CpG 1018 increases antibody concentrations, stimulates helper (CD4+) and cytotoxic (CD8+) T cell populations and generates robust T and B cell DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate; EMERYVILLE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, andDYNAVAX EUROPE
BRENT MACGREGOR
Brent MacGregor. Mr. MacGregor was appointed to the Dynavax board in July 2020. Mr. MacGregor previously served as Senior Vice-President, Global Commercial Operations at Seqirus, a CSL Limited company. At Seqirus, Mr. MacGregor led a global team of 280 people in sales, marketing, commercial development, public policy and businessdevelopment
DYNAVAX'S HEPLISAV-B™ [HEPATITIS B VACCINE (RECOMBINANT BERKELEY, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously in favor of including HEPLISAV-B on its list of ACIP recommended products for use to vaccinate adults against hepatitis B. HEPLISAV-B was DYNAVAX TECHNOLOGIES COVID-19 Information and Resources. During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B ® ; maintaining our financial strength and ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.INVESTOR RELATIONS
Dynavax Overview. Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation to develop cutting-edge vaccines. The Company’s first commercial product, HEPLISAV-B® ,a
JOB OPPORTUNITIES AT DYNAVAX TECHNOLOGIES Dynavax is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status.PRESS RELEASES
Press Releases. Date. Title. Files. May 27, 2021. Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany. PDF Version. May 19, 2021. Dynavax to Present at the William Blair 41st Annual Growth Stock Conference. CPG 1018 | TOLL-LIKE RECEPTOR 9 (TLR9) AGONIST ADJUVANT CpG 1018. CpG 1018 has been studied clinically and developed as a vaccine adjuvant for Dynavax’s hepatitis B vaccine, HEPLISAV-B. The pre-clinical and clinical studies demonstrate that the addition of CpG 1018 increases antibody concentrations, stimulates helper (CD4+) and cytotoxic (CD8+) T cell populations and generates robust T and B cell DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate; EMERYVILLE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, andDYNAVAX EUROPE
BRENT MACGREGOR
Brent MacGregor. Mr. MacGregor was appointed to the Dynavax board in July 2020. Mr. MacGregor previously served as Senior Vice-President, Global Commercial Operations at Seqirus, a CSL Limited company. At Seqirus, Mr. MacGregor led a global team of 280 people in sales, marketing, commercial development, public policy and businessdevelopment
DYNAVAX'S HEPLISAV-B™ [HEPATITIS B VACCINE (RECOMBINANT BERKELEY, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously in favor of including HEPLISAV-B on its list of ACIP recommended products for use to vaccinate adults against hepatitis B. HEPLISAV-B was HEPLISAV-B | DYNAVAX TECHNOLOGIES HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. 1 HEPLISAV-B recommended by CDC Advisory Committee on Immunization Practices (ACIP) for the Prevention of Hepatitis B in Adults. 2 INDICATION CAREERS AT DYNAVAX TECHNOLOGIES Join Our Team. Dynavax is focused on developing innovative therapies based on breakthroughs in scientific discovery to make a difference in the lives of patients. We are a dynamic team with diverse backgrounds, and we like it that way. We are a values-based organization that looks out for our employees and fosters a rewarding work environment. CONTACT DYNAVAX TECHNOLOGIES Dynavax Technologies Corporation. 2100 Powell Street, Suite 900 Emeryville, CA 94608 Phone: +1.510.848.5100 Toll Free: +1.877.848.5100 Fax: +1.510.848.1327 S-TRIMER, A COVID-19 SUBUNIT VACCINE CANDIDATE, INDUCES 4 gp120, but not monomeric gp120 (14-17), implies that preserving the native trimeric conformation of viral antigens may be important to thefuture success of
ONGOING STUDIES LISTING Ongoing Studies DV2-HBV-25 (Post-marketing Study for Acute Myocardial Infarction Events) The HBV-25 post-marketing observational surveillance study began in August 2018 and will evaluate the occurrence of acute myocardial infarction (AMI) in approximately 30,000 patients who receive HEPLISAV-B ® and approximately 30,000 patients who receive another hepatitis B vaccine. MEDIGEN'S COVID-19 VACCINE COMBINED WITH DYNAVAX'S CPG MVC's Phase 1 study is an open-label, single-center, staggered dose-escalation study intended to assess the safety and immunogenicity of the stable prefusion form of SARS-CoV-2 recombinant spike protein S-2P at three dose levels (low, medium and high) adjuvanted with CpG 1018 plus alum, in approximately 45 healthy subjects 20 to 50 years ofage.
ONGOING STUDIES
Dynavax Technologies ongoing studies, we have a number of ongoing clinical post marketing and investigational studies. DYNAVAX ANNOUNCES AGREEMENT WITH BAVARIAN NORDIC FOR EMERYVILLE, Calif., May 27, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B in DYNAVAX ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF Dynavax is providing CpG 1018, the adjuvant contained in HEPLISAV-B, to support the rapid development of a COVID-19 vaccine. EMERYVILLE, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it is collaborating with the University of Queensland DYNAVAX ANNOUNCES STRATEGIC RESTRUCTURING TO FOCUS ON ITS The Investor Relations website contains information about Dynavax Technologies Corporation's business for stockholders, potential investors, and financial analysts. DYNAVAX TECHNOLOGIES COVID-19 Information and Resources. During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B ® ; maintaining our financial strength and ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.INVESTOR RELATIONS
Dynavax Overview. Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation to develop cutting-edge vaccines. The Company’s first commercial product, HEPLISAV-B® ,a
PRESS RELEASES
Press Releases. Date. Title. Files. May 27, 2021. Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany. PDF Version. May 19, 2021. Dynavax to Present at the William Blair 41st Annual Growth Stock Conference. HEPLISAV-B | DYNAVAX TECHNOLOGIES HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. 1 HEPLISAV-B recommended by CDC Advisory Committee on Immunization Practices (ACIP) for the Prevention of Hepatitis B in Adults. 2 INDICATION JOB OPPORTUNITIES AT DYNAVAX TECHNOLOGIES Dynavax is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status. POSITIVE PHASE 1/2 RESULTS FOR VALNEVA'S INACTIVATED COVID EMERYVILLE, Calif., April 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Valneva SE reported positive initial results for Part A of the Phase 1/2 clinical trial of Valneva's inactivated COVID-19 vaccine candidate, VLA2001, using Dynavax's CpGDYNAVAX EUROPE
CPG 1018 | TOLL-LIKE RECEPTOR 9 (TLR9) AGONIST ADJUVANT CpG 1018. CpG 1018 has been studied clinically and developed as a vaccine adjuvant for Dynavax’s hepatitis B vaccine, HEPLISAV-B. The pre-clinical and clinical studies demonstrate that the addition of CpG 1018 increases antibody concentrations, stimulates helper (CD4+) and cytotoxic (CD8+) T cell populations and generates robust T and B cell DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate; EMERYVILLE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and DYNAVAX TECHNOLOGIES COVID-19 Information and Resources. During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B ® ; maintaining our financial strength and ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.INVESTOR RELATIONS
Dynavax Overview. Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation to develop cutting-edge vaccines. The Company’s first commercial product, HEPLISAV-B® ,a
PRESS RELEASES
Press Releases. Date. Title. Files. May 27, 2021. Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany. PDF Version. May 19, 2021. Dynavax to Present at the William Blair 41st Annual Growth Stock Conference. HEPLISAV-B | DYNAVAX TECHNOLOGIES HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. 1 HEPLISAV-B recommended by CDC Advisory Committee on Immunization Practices (ACIP) for the Prevention of Hepatitis B in Adults. 2 INDICATION JOB OPPORTUNITIES AT DYNAVAX TECHNOLOGIES Dynavax is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status. POSITIVE PHASE 1/2 RESULTS FOR VALNEVA'S INACTIVATED COVID EMERYVILLE, Calif., April 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Valneva SE reported positive initial results for Part A of the Phase 1/2 clinical trial of Valneva's inactivated COVID-19 vaccine candidate, VLA2001, using Dynavax's CpG CPG 1018 | TOLL-LIKE RECEPTOR 9 (TLR9) AGONIST ADJUVANT CpG 1018. CpG 1018 has been studied clinically and developed as a vaccine adjuvant for Dynavax’s hepatitis B vaccine, HEPLISAV-B. The pre-clinical and clinical studies demonstrate that the addition of CpG 1018 increases antibody concentrations, stimulates helper (CD4+) and cytotoxic (CD8+) T cell populations and generates robust T and B cellDYNAVAX EUROPE
DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate; EMERYVILLE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation. CONTACT DYNAVAX TECHNOLOGIES Dynavax Technologies Corporation. 2100 Powell Street, Suite 900 Emeryville, CA 94608 Phone: +1.510.848.5100 Toll Free: +1.877.848.5100 Fax: +1.510.848.1327 ONGOING STUDIES LISTING Ongoing Studies DV2-HBV-25 (Post-marketing Study for Acute Myocardial Infarction Events) The HBV-25 post-marketing observational surveillance study began in August 2018 and will evaluate the occurrence of acute myocardial infarction (AMI) in approximately 30,000 patients who receive HEPLISAV-B ® and approximately 30,000 patients who receive another hepatitis B vaccine.ONGOING STUDIES
Dynavax Technologies ongoing studies, we have a number of ongoing clinical post marketing and investigational studies. DYNAVAX ANNOUNCES AGREEMENT WITH BAVARIAN NORDIC FOR EMERYVILLE, Calif., May 27, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B in DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate; EMERYVILLE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and DYNAVAX ANNOUNCES GRANT TO SCALE UP CPG 1018 ADJUVANT EMERYVILLE, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a grant from the Bill & Melinda Gates Foundation of $3.4 million to scale up production batch size to allow for increased capacity of Dynavax’s CpG 1018 advanced adjuvant toSEC FILINGS
8-K. Report of unscheduled material events or corporate event. 0001564590-21-024953.pdf. 0001564590-21-024953.rtf. 0001564590-21-024953.xls. View HTML. May 06, 2021. 10-Q. Quarterly report which provides a continuing view of a company's financialposition.
DYNAVAX ANNOUNCES STRATEGIC RESTRUCTURING TO FOCUS ON ITS The Investor Relations website contains information about Dynavax Technologies Corporation's business for stockholders, potential investors, and financial analysts. DYNAVAX'S HEPLISAV-B™ [HEPATITIS B VACCINE (RECOMBINANT BERKELEY, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously in favor of including HEPLISAV-B on its list of ACIP recommended products for use to vaccinate adults against hepatitis B. HEPLISAV-B was DYNAVAX TECHNOLOGIES COVID-19 Information and Resources. During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B ® ; maintaining our financial strength and ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.INVESTOR RELATIONS
Dynavax Overview. Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation to develop cutting-edge vaccines. The Company’s first commercial product, HEPLISAV-B® ,a
PRESS RELEASES
Press Releases. Date. Title. Files. May 27, 2021. Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany. PDF Version. May 19, 2021. Dynavax to Present at the William Blair 41st Annual Growth Stock Conference. HEPLISAV-B | DYNAVAX TECHNOLOGIES HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. 1 HEPLISAV-B recommended by CDC Advisory Committee on Immunization Practices (ACIP) for the Prevention of Hepatitis B in Adults. 2 INDICATION JOB OPPORTUNITIES AT DYNAVAX TECHNOLOGIES Dynavax is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status. POSITIVE PHASE 1/2 RESULTS FOR VALNEVA'S INACTIVATED COVID EMERYVILLE, Calif., April 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Valneva SE reported positive initial results for Part A of the Phase 1/2 clinical trial of Valneva's inactivated COVID-19 vaccine candidate, VLA2001, using Dynavax's CpG CPG 1018 | TOLL-LIKE RECEPTOR 9 (TLR9) AGONIST ADJUVANT CpG 1018. CpG 1018 has been studied clinically and developed as a vaccine adjuvant for Dynavax’s hepatitis B vaccine, HEPLISAV-B. The pre-clinical and clinical studies demonstrate that the addition of CpG 1018 increases antibody concentrations, stimulates helper (CD4+) and cytotoxic (CD8+) T cell populations and generates robust T and B cellDYNAVAX EUROPE
DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate; EMERYVILLE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and DYNAVAX TECHNOLOGIES COVID-19 Information and Resources. During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B ® ; maintaining our financial strength and ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.INVESTOR RELATIONS
Dynavax Overview. Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation to develop cutting-edge vaccines. The Company’s first commercial product, HEPLISAV-B® ,a
PRESS RELEASES
Press Releases. Date. Title. Files. May 27, 2021. Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany. PDF Version. May 19, 2021. Dynavax to Present at the William Blair 41st Annual Growth Stock Conference. HEPLISAV-B | DYNAVAX TECHNOLOGIES HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. 1 HEPLISAV-B recommended by CDC Advisory Committee on Immunization Practices (ACIP) for the Prevention of Hepatitis B in Adults. 2 INDICATION JOB OPPORTUNITIES AT DYNAVAX TECHNOLOGIES Dynavax is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status. POSITIVE PHASE 1/2 RESULTS FOR VALNEVA'S INACTIVATED COVID EMERYVILLE, Calif., April 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Valneva SE reported positive initial results for Part A of the Phase 1/2 clinical trial of Valneva's inactivated COVID-19 vaccine candidate, VLA2001, using Dynavax's CpG CPG 1018 | TOLL-LIKE RECEPTOR 9 (TLR9) AGONIST ADJUVANT CpG 1018. CpG 1018 has been studied clinically and developed as a vaccine adjuvant for Dynavax’s hepatitis B vaccine, HEPLISAV-B. The pre-clinical and clinical studies demonstrate that the addition of CpG 1018 increases antibody concentrations, stimulates helper (CD4+) and cytotoxic (CD8+) T cell populations and generates robust T and B cellDYNAVAX EUROPE
DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate; EMERYVILLE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation. CONTACT DYNAVAX TECHNOLOGIES Dynavax Technologies Corporation. 2100 Powell Street, Suite 900 Emeryville, CA 94608 Phone: +1.510.848.5100 Toll Free: +1.877.848.5100 Fax: +1.510.848.1327 ONGOING STUDIES LISTING Ongoing Studies DV2-HBV-25 (Post-marketing Study for Acute Myocardial Infarction Events) The HBV-25 post-marketing observational surveillance study began in August 2018 and will evaluate the occurrence of acute myocardial infarction (AMI) in approximately 30,000 patients who receive HEPLISAV-B ® and approximately 30,000 patients who receive another hepatitis B vaccine.ONGOING STUDIES
Dynavax Technologies ongoing studies, we have a number of ongoing clinical post marketing and investigational studies. DYNAVAX ANNOUNCES AGREEMENT WITH BAVARIAN NORDIC FOR EMERYVILLE, Calif., May 27, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B in DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate; EMERYVILLE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and DYNAVAX ANNOUNCES GRANT TO SCALE UP CPG 1018 ADJUVANT EMERYVILLE, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a grant from the Bill & Melinda Gates Foundation of $3.4 million to scale up production batch size to allow for increased capacity of Dynavax’s CpG 1018 advanced adjuvant toSEC FILINGS
8-K. Report of unscheduled material events or corporate event. 0001564590-21-024953.pdf. 0001564590-21-024953.rtf. 0001564590-21-024953.xls. View HTML. May 06, 2021. 10-Q. Quarterly report which provides a continuing view of a company's financialposition.
DYNAVAX ANNOUNCES STRATEGIC RESTRUCTURING TO FOCUS ON ITS The Investor Relations website contains information about Dynavax Technologies Corporation's business for stockholders, potential investors, and financial analysts. DYNAVAX'S HEPLISAV-B™ [HEPATITIS B VACCINE (RECOMBINANT BERKELEY, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously in favor of including HEPLISAV-B on its list of ACIP recommended products for use to vaccinate adults against hepatitis B. HEPLISAV-B was DYNAVAX TECHNOLOGIES COVID-19 Information and Resources. During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B ® ; maintaining our financial strength and ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.INVESTOR RELATIONS
Dynavax Overview. Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation to develop cutting-edge vaccines. The Company’s first commercial product, HEPLISAV-B® ,a
PRESS RELEASES
Press Releases. Date. Title. Files. May 27, 2021. Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany. PDF Version. May 19, 2021. Dynavax to Present at the William Blair 41st Annual Growth Stock Conference. JOB OPPORTUNITIES AT DYNAVAX TECHNOLOGIES Dynavax is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status. CPG 1018 | TOLL-LIKE RECEPTOR 9 (TLR9) AGONIST ADJUVANT CpG 1018. CpG 1018 has been studied clinically and developed as a vaccine adjuvant for Dynavax’s hepatitis B vaccine, HEPLISAV-B. The pre-clinical and clinical studies demonstrate that the addition of CpG 1018 increases antibody concentrations, stimulates helper (CD4+) and cytotoxic (CD8+) T cell populations and generates robust T and B cell DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate; EMERYVILLE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, andDYNAVAX EUROPE
DYNAVAX ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF Dynavax is providing CpG 1018, the adjuvant contained in HEPLISAV-B, to support the rapid development of a COVID-19 vaccine. EMERYVILLE, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it is collaborating with the University of QueenslandBRENT MACGREGOR
Brent MacGregor. Mr. MacGregor was appointed to the Dynavax board in July 2020. Mr. MacGregor previously served as Senior Vice-President, Global Commercial Operations at Seqirus, a CSL Limited company. At Seqirus, Mr. MacGregor led a global team of 280 people in sales, marketing, commercial development, public policy and businessdevelopment
DYNAVAX TECHNOLOGIES COVID-19 Information and Resources. During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B ® ; maintaining our financial strength and ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.INVESTOR RELATIONS
Dynavax Overview. Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation to develop cutting-edge vaccines. The Company’s first commercial product, HEPLISAV-B® ,a
PRESS RELEASES
Press Releases. Date. Title. Files. May 27, 2021. Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany. PDF Version. May 19, 2021. Dynavax to Present at the William Blair 41st Annual Growth Stock Conference. JOB OPPORTUNITIES AT DYNAVAX TECHNOLOGIES Dynavax is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status. CPG 1018 | TOLL-LIKE RECEPTOR 9 (TLR9) AGONIST ADJUVANT CpG 1018. CpG 1018 has been studied clinically and developed as a vaccine adjuvant for Dynavax’s hepatitis B vaccine, HEPLISAV-B. The pre-clinical and clinical studies demonstrate that the addition of CpG 1018 increases antibody concentrations, stimulates helper (CD4+) and cytotoxic (CD8+) T cell populations and generates robust T and B cell DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate; EMERYVILLE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, andDYNAVAX EUROPE
DYNAVAX ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF Dynavax is providing CpG 1018, the adjuvant contained in HEPLISAV-B, to support the rapid development of a COVID-19 vaccine. EMERYVILLE, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it is collaborating with the University of QueenslandBRENT MACGREGOR
Brent MacGregor. Mr. MacGregor was appointed to the Dynavax board in July 2020. Mr. MacGregor previously served as Senior Vice-President, Global Commercial Operations at Seqirus, a CSL Limited company. At Seqirus, Mr. MacGregor led a global team of 280 people in sales, marketing, commercial development, public policy and businessdevelopment
ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation. CAREERS AT DYNAVAX TECHNOLOGIES Join Our Team. Dynavax is focused on developing innovative therapies based on breakthroughs in scientific discovery to make a difference in the lives of patients. We are a dynamic team with diverse backgrounds, and we like it that way. We are a values-based organization that looks out for our employees and fosters a rewarding work environment.ONGOING STUDIES
Dynavax Technologies ongoing studies, we have a number of ongoing clinical post marketing and investigational studies. POSITIVE PHASE 1/2 RESULTS FOR VALNEVA'S INACTIVATED COVID EMERYVILLE, Calif., April 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Valneva SE reported positive initial results for Part A of the Phase 1/2 clinical trial of Valneva's inactivated COVID-19 vaccine candidate, VLA2001, using Dynavax's CpG DYNAVAX ANNOUNCES AGREEMENT WITH BAVARIAN NORDIC FOR EMERYVILLE, Calif., May 27, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B in S-TRIMER, A COVID-19 SUBUNIT VACCINE CANDIDATE, INDUCES 4 gp120, but not monomeric gp120 (14-17), implies that preserving the native trimeric conformation of viral antigens may be important to thefuture success of
SEC FILINGS
8-K. Report of unscheduled material events or corporate event. 0001564590-21-024953.pdf. 0001564590-21-024953.rtf. 0001564590-21-024953.xls. View HTML. May 06, 2021. 10-Q. Quarterly report which provides a continuing view of a company's financialposition.
DYNAVAX ANNOUNCES STRATEGIC RESTRUCTURING TO FOCUS ON ITS The Investor Relations website contains information about Dynavax Technologies Corporation's business for stockholders, potential investors, and financial analysts. EVENTS & PRESENTATIONS The Investor Relations website contains information about Dynavax Technologies Corporation's business for stockholders, potential investors, and financial analysts. DYNAVAX'S HEPLISAV-B™ [HEPATITIS B VACCINE (RECOMBINANT BERKELEY, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously in favor of including HEPLISAV-B on its list of ACIP recommended products for use to vaccinate adults against hepatitis B. HEPLISAV-B was DYNAVAX TECHNOLOGIES COVID-19 Information and Resources. During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B ® ; maintaining our financial strength and ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.INVESTOR RELATIONS
Dynavax Overview. Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation to develop cutting-edge vaccines. The Company’s first commercial product, HEPLISAV-B® ,a
HEPLISAV-B | DYNAVAX TECHNOLOGIES HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. 1 HEPLISAV-B recommended by CDC Advisory Committee on Immunization Practices (ACIP) for the Prevention of Hepatitis B in Adults. 2 INDICATION CAREERS AT DYNAVAX TECHNOLOGIES Join Our Team. Dynavax is focused on developing innovative therapies based on breakthroughs in scientific discovery to make a difference in the lives of patients. We are a dynamic team with diverse backgrounds, and we like it that way. We are a values-based organization that looks out for our employees and fosters a rewarding work environment. CONTACT DYNAVAX TECHNOLOGIES Dynavax Technologies Corporation. 2100 Powell Street, Suite 900 Emeryville, CA 94608 Phone: +1.510.848.5100 Toll Free: +1.877.848.5100 Fax: +1.510.848.1327 JOB OPPORTUNITIES AT DYNAVAX TECHNOLOGIES Dynavax is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status. DYNAVAX TECHNOLOGIES COVID-19 Information and Resources. During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B ® ; maintaining our financial strength and ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.INVESTOR RELATIONS
Dynavax Overview. Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation to develop cutting-edge vaccines. The Company’s first commercial product, HEPLISAV-B® ,a
HEPLISAV-B | DYNAVAX TECHNOLOGIES HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. 1 HEPLISAV-B recommended by CDC Advisory Committee on Immunization Practices (ACIP) for the Prevention of Hepatitis B in Adults. 2 INDICATION CAREERS AT DYNAVAX TECHNOLOGIES Join Our Team. Dynavax is focused on developing innovative therapies based on breakthroughs in scientific discovery to make a difference in the lives of patients. We are a dynamic team with diverse backgrounds, and we like it that way. We are a values-based organization that looks out for our employees and fosters a rewarding work environment. CONTACT DYNAVAX TECHNOLOGIES Dynavax Technologies Corporation. 2100 Powell Street, Suite 900 Emeryville, CA 94608 Phone: +1.510.848.5100 Toll Free: +1.877.848.5100 Fax: +1.510.848.1327 JOB OPPORTUNITIES AT DYNAVAX TECHNOLOGIES Dynavax is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status. CAREERS AT DYNAVAX TECHNOLOGIES Join Our Team. Dynavax is focused on developing innovative therapies based on breakthroughs in scientific discovery to make a difference in the lives of patients. We are a dynamic team with diverse backgrounds, and we like it that way. We are a values-based organization that looks out for our employees and fosters a rewarding work environment. ONGOING STUDIES LISTING Ongoing Studies DV2-HBV-25 (Post-marketing Study for Acute Myocardial Infarction Events) The HBV-25 post-marketing observational surveillance study began in August 2018 and will evaluate the occurrence of acute myocardial infarction (AMI) in approximately 30,000 patients who receive HEPLISAV-B ® and approximately 30,000 patients who receive another hepatitis B vaccine.ONGOING STUDIES
Dynavax Technologies ongoing studies, we have a number of ongoing clinical post marketing and investigational studies.PRESS RELEASES
Press Releases. Date. Title. Files. May 27, 2021. Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany. PDF Version. May 19, 2021. Dynavax to Present at the William Blair 41st Annual Growth Stock Conference.OUR SCIENCE
TLR9 Agonists. Central to the activity of our TLR9 agonists are dendritic cells. Upon engaging TLR9, dendritic cells provide two important functions for stimulating the immune system: 1) They secrete interferon-α and other cytokines, which directly and indirectly lead to activation of other innate immune cells and promotes homing of immune cells to the tumor; and 2)They are stimulated to POSITIVE PHASE 1/2 RESULTS FOR VALNEVA'S INACTIVATED COVID EMERYVILLE, Calif., April 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Valneva SE reported positive initial results for Part A of the Phase 1/2 clinical trial of Valneva's inactivated COVID-19 vaccine candidate, VLA2001, using Dynavax's CpG DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate; EMERYVILLE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, andANNUALS AND PROXIES
Annuals and Proxies. Annuals and Proxies. Title. Documents. 2021 Proxy Statement and 2020 Annual Report. 2021 Proxy Statement and 2020 Annual Report. Additional proxy soliciting materials - definitive. Additional proxy soliciting materials - definitive. Overview.TERMS OF USE
DYNAVAX TERMS OF USE. Effective Date: Dec 19, 2018. These Terms of Use are entered into by and between you and Dynavax Technologies Corporation, Dynavax GmbH and DYNAVAX ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF Dynavax is providing CpG 1018, the adjuvant contained in HEPLISAV-B, to support the rapid development of a COVID-19 vaccine. EMERYVILLE, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it is collaborating with the University of Queensland DYNAVAX TECHNOLOGIES COVID-19 Information and Resources. During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B ® ; maintaining our financial strength and ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.INVESTOR RELATIONS
Dynavax Overview. Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation to develop cutting-edge vaccines. The Company’s first commercial product, HEPLISAV-B® ,a
HEPLISAV-B | DYNAVAX TECHNOLOGIES HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. 1 HEPLISAV-B recommended by CDC Advisory Committee on Immunization Practices (ACIP) for the Prevention of Hepatitis B in Adults. 2 INDICATION CAREERS AT DYNAVAX TECHNOLOGIES Join Our Team. Dynavax is focused on developing innovative therapies based on breakthroughs in scientific discovery to make a difference in the lives of patients. We are a dynamic team with diverse backgrounds, and we like it that way. We are a values-based organization that looks out for our employees and fosters a rewarding work environment. CONTACT DYNAVAX TECHNOLOGIES Dynavax Technologies Corporation. 2100 Powell Street, Suite 900 Emeryville, CA 94608 Phone: +1.510.848.5100 Toll Free: +1.877.848.5100 Fax: +1.510.848.1327 JOB OPPORTUNITIES AT DYNAVAX TECHNOLOGIES Dynavax is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status. DYNAVAX TECHNOLOGIES COVID-19 Information and Resources. During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B ® ; maintaining our financial strength and ABOUT | MANAGEMENT | BOARD OF DIRECTOR | DYNAVAX TECHNOLOGIES About Dynavax Technologies. Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.INVESTOR RELATIONS
Dynavax Overview. Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation to develop cutting-edge vaccines. The Company’s first commercial product, HEPLISAV-B® ,a
HEPLISAV-B | DYNAVAX TECHNOLOGIES HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. 1 HEPLISAV-B recommended by CDC Advisory Committee on Immunization Practices (ACIP) for the Prevention of Hepatitis B in Adults. 2 INDICATION CAREERS AT DYNAVAX TECHNOLOGIES Join Our Team. Dynavax is focused on developing innovative therapies based on breakthroughs in scientific discovery to make a difference in the lives of patients. We are a dynamic team with diverse backgrounds, and we like it that way. We are a values-based organization that looks out for our employees and fosters a rewarding work environment. CONTACT DYNAVAX TECHNOLOGIES Dynavax Technologies Corporation. 2100 Powell Street, Suite 900 Emeryville, CA 94608 Phone: +1.510.848.5100 Toll Free: +1.877.848.5100 Fax: +1.510.848.1327 JOB OPPORTUNITIES AT DYNAVAX TECHNOLOGIES Dynavax is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status. CAREERS AT DYNAVAX TECHNOLOGIES Join Our Team. Dynavax is focused on developing innovative therapies based on breakthroughs in scientific discovery to make a difference in the lives of patients. We are a dynamic team with diverse backgrounds, and we like it that way. We are a values-based organization that looks out for our employees and fosters a rewarding work environment. ONGOING STUDIES LISTING Ongoing Studies DV2-HBV-25 (Post-marketing Study for Acute Myocardial Infarction Events) The HBV-25 post-marketing observational surveillance study began in August 2018 and will evaluate the occurrence of acute myocardial infarction (AMI) in approximately 30,000 patients who receive HEPLISAV-B ® and approximately 30,000 patients who receive another hepatitis B vaccine.ONGOING STUDIES
Dynavax Technologies ongoing studies, we have a number of ongoing clinical post marketing and investigational studies.PRESS RELEASES
Press Releases. Date. Title. Files. May 27, 2021. Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany. PDF Version. May 19, 2021. Dynavax to Present at the William Blair 41st Annual Growth Stock Conference.OUR SCIENCE
TLR9 Agonists. Central to the activity of our TLR9 agonists are dendritic cells. Upon engaging TLR9, dendritic cells provide two important functions for stimulating the immune system: 1) They secrete interferon-α and other cytokines, which directly and indirectly lead to activation of other innate immune cells and promotes homing of immune cells to the tumor; and 2)They are stimulated to POSITIVE PHASE 1/2 RESULTS FOR VALNEVA'S INACTIVATED COVID EMERYVILLE, Calif., April 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Valneva SE reported positive initial results for Part A of the Phase 1/2 clinical trial of Valneva's inactivated COVID-19 vaccine candidate, VLA2001, using Dynavax's CpG DYNAVAX AND SINOVAC ANNOUNCE COLLABORATION TO DEVELOP A The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidate; EMERYVILLE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, andANNUALS AND PROXIES
Annuals and Proxies. Annuals and Proxies. Title. Documents. 2021 Proxy Statement and 2020 Annual Report. 2021 Proxy Statement and 2020 Annual Report. Additional proxy soliciting materials - definitive. Additional proxy soliciting materials - definitive. Overview.TERMS OF USE
DYNAVAX TERMS OF USE. Effective Date: Dec 19, 2018. These Terms of Use are entered into by and between you and Dynavax Technologies Corporation, Dynavax GmbH and DYNAVAX ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF Dynavax is providing CpG 1018, the adjuvant contained in HEPLISAV-B, to support the rapid development of a COVID-19 vaccine. EMERYVILLE, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it is collaborating with the University of Queensland PROTECTION FOR AN UNPREDICTABLE WORLD We are developing cutting-edge vaccines by utilizing our innovative adjuvant technology and our expertise of Toll-like Receptor (TLR) biology to modulate the immune system.TLR Biology
HEPLISAV-B®
COVID-19 INFORMATION AND RESOURCES During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access toHEPLISAV-B® ;
maintaining our financial strength and stability; and supporting efforts to develop a COVID-19 vaccine.learn more.
Learn more about our ProductRECENT NEWS
May 27, 2021
Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, inGermany
May 19, 2021
Dynavax to Present at the William Blair 41st Annual Growth StockConference
View All News
* About
* Overview
* Management
* Board of Directors* Dynavax Europe
* Product
* HEPLISAV-B
* Science
* Overview
* Publications & Presentations* CpG 1018
* Ongoing Studies
* Overview
* Ongoing Studies Listing* Partnership
* Investors
* Overview
* Press Releases
* Events & Presentations* Stock Information
* Analyst Coverage
* Financials
* SEC Filings
* Annuals and Proxies * Corporate Governance and Compliance * Board of Directors * Committee Composition* Contact the Board
* Contact Us
* Careers
* Join Our Team
* Job Opportunities
* Benefits
* Contact
* Home
* About
* Overview
* Management
* Board of Directors* Dynavax Europe
* Product
* HEPLISAV-B
* Science
* Overview
* Publications & Presentations* CpG 1018
* Ongoing Studies
* Overview
* Ongoing Studies Listing* Partnership
* Investors
* Overview
* Press Releases
* Events & Presentations* Stock Information
* Analyst Coverage
* Financials
* SEC Filings
* Annuals and Proxies * Corporate Governance and Compliance * Board of Directors * Committee Composition* Contact the Board
* Contact Us
* Careers
* Join Our Team
* Job Opportunities
* Benefits
* Contact
* Twitter__ LinkedIn__* Terms of Use
* Privacy Notice
2021 Dynavax Technologies. All rights reserved.* Terms of Use
* Privacy Notice
Website Design : Hane Chow, Inc.US-20-00-00098
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0